MD Anderson Cancer Center
The University of Texas
Houston, TX
Accepting patients
TL118
A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
- Phase 2
Accepting patients
NAUTIKA1
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
- Phase 2
Accepting patients
Larotrectinib
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
LANTERN
Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
- Tyrosine Kinase (TK) Inhibitor
- Radiation
- Phase 2
Accepting patients
VMD-928
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results